Jamunarani Veeraraghavan, Ph.D.,

Assistant Professor

Email

jveerara@bcm.edu

Positions

Assistant Professor: Breast Center - Schiff-Osborne lab
Baylor College of Medicine
Houston, TX, US

Member: Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Education

PhD from The University of Oklahoma Health Sciences Center: 05/2012 - Oklahoma City, Oklahoma, United States; Pathology

Professional Interests

Cancer cell biology, Gene fusion, Preclinical tumor models, HER2-positive breast cancer, Precision Medicine, Treatment resistance, ERBB2 mutations, HER2-targeted therapy

Professional Statement

Through a correlative biomarker study using tumor specimens from chemotherapy-sparing neoadjuvant clinical trial, we recently demonstrated that there is a clinical subtype in breast cancer with high HER2 amplification and intact PI3K pathway that is especially sensitive to HER2-targeted therapy, without chemotherapy.
My current primary research interests are: i) delineate the mechanisms of resistance to potent HER2-targeted therapies, ii) unravel the genomic complexity of HER2-positive metastatic breast cancer, with a particular focus on brain metastasis, and iii) develop treatment strategies to effectively circumvent resistance and metastasis in HER2-positive breast cancer.

Websites

VIICTR Publications List

Selected Publications

Veeraraghavan J, Tan Y, Cao X, Kim JA, Wang X, Chamness G.C, Maiti S.N, Laurence J.N. Cooper, Edwards D.P, Contreras A, Hilsenbeck S.G, Chang E.C, Schiff R and Wang X-S. " Recurrent ESR1–CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers " Nat Commun. 2014 Aug 7; 5 (1) : 1-12.
Pubmed PMID: 25099679.
Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, et al.,. " HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer " Clin Cancer Res. 2017 Jan 9; 23 (17) : 5123-5134.
Pubmed PMID: 28487443.
Veeraraghavan J, De Angelis C, Reis-Filho JS, Prat A, Rimawi MF, Pascual T, Osborne CK, Schiff R.. " De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance " Breast. 2017 Aug ; 34 (Suppl) : S19-S26.
Pubmed PMID: 28687441.
Goutsouliak K*, Veeraraghavan J*, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. *contributed equally. " Towards personalized treatment for early stage HER2-positive breast cancer " Nat Rev Clin Oncol. 2020 Apr ; 17 (4) : 233-250.
Pubmed PMID: 31836877.
Veeraraghavan J, Mao J, Hu Y, Wang X-S. " Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications " Breast Cancer Res Treat. 2016 Jul ; 158 (2) : 219-232.
Pubmed PMID: 27372070.
Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, at al.,. " A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer " Ann Oncol. 2019 Jun ; 30 (6) : 927-933.
Pubmed PMID: 30903140.
Liu C*, Veeraraghavan J*, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, Wang X-S, *contributed equally. " A novel neoplastic fusion transcript, RAD51AP1-DYRK4, confers sensitivity to the MEK inhibitor trametinib in aggressive breast cancers " Clin Cancer Res. 2021 Feb 1; 27 (3) : 785-798.
Pubmed PMID: 33172895.
Veeraraghavan J, Natarajan M, Herman TS and Aravindan N. " Radiation-triggered tumor necrosis factor (TNF) α-NFκB cross-signaling favors survival advantage in human neuroblastoma cells " J Biol Chem. 2011 Jun 17; 286 (24) : 21588-21600.
Pubmed PMID: 21527635.

Skills

Cancer cell and molecular biology